Shots:

• Amathus to receive upfront and will be eligible for ~$500M milestones/program- if Merck exercise its option and will be responsible for identifying & progressing novel chaperone activators through preclinical discovery
• Merck to get an option to acquire Amathus Therapeutics along with its pipeline of mitochondrial targeted candidate to treat neurodegenerative disorders and renal diseases
• Following the exercise of the option- Merck will lead the clinical development and commercialization of therapies for neurodegenerative diseases

 ­ Ref: Businesswire | Image: Merck